APA (7th ed.) Citation

ME, S., R, Z., MR, G., ML, B., EP, S., Y, Y., . . . TS, A. (2022). Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neuro-oncology advances, 4(1), vdac152. https://doi.org/10.1093/noajnl/vdac152

Chicago Style (17th ed.) Citation

ME, Scheurer, et al. "Germline Polymorphisms in MGMT Associated with Temozolomide-related Myelotoxicity Risk in Patients with Glioblastoma Treated on NRG Oncology/RTOG 0825." Neuro-oncology Advances 4, no. 1 (2022): vdac152. https://doi.org/10.1093/noajnl/vdac152.

MLA (9th ed.) Citation

ME, Scheurer, et al. "Germline Polymorphisms in MGMT Associated with Temozolomide-related Myelotoxicity Risk in Patients with Glioblastoma Treated on NRG Oncology/RTOG 0825." Neuro-oncology Advances, vol. 4, no. 1, 2022, p. vdac152, https://doi.org/10.1093/noajnl/vdac152.